Quest PharmaTech Inc. (TSXV:QPT)
Canada · Delayed Price · Currency is CAD | Market Cap | 5.92M +40.0% |
| Revenue (ttm) | n/a |
| Net Income | 5.00M |
| EPS | 0.03 |
| Shares Out | 169.13M |
| PE Ratio | 1.18 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 0.0300 |
| Previous Close | 0.0350 |
| Day's Range | 0.0300 - 0.0300 |
| 52-Week Range | 0.0250 - 0.0550 |
| Beta | -0.31 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jun 12, 2026 |
About Quest PharmaTech
Quest PharmaTech Inc., a pharmaceutical company, engages in the development of novel therapeutics for the treatment of targeted cancer. The company’s lead product candidate is Mab AR 9.6 against truncated O-glycan on MUC16 for the potential cancer targets, including pancreatic, colon, leukemia, ovarian, and breast cancer. Quest PharmaTech Inc. is headquartered in Edmonton, Canada. [Read more]
Financial Performance
Financial StatementsNews
Quest PharmaTech Provides Corporate Update including Voluntary Adoption of CSA Blanket Order 51-93 to File Financial Statements and MD&A on Semi-Annual Basis
EDMONTON, Alberta, May 29, 2026 (GLOBE NEWSWIRE) -- Quest PharmaTech Inc. (TSX-V: QPT) (“Quest” or the “Company”), a Canadian based pharmaceutical company developing products to improve the quality of...
Quest PharmaTech Announces Results from AGM
EDMONTON, Alberta, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Quest PharmaTech Inc. (TSX-V:QPT) (“Quest” or the “Company”) today announced the results of its August 25, 2025 annual general meeting of sharehold...
Quest PharmaTech Announces Opposition to OQPBIOM's Acquisition of AdBioTech
EDMONTON, Alberta, June 10, 2025 (GLOBE NEWSWIRE) -- Quest PharmaTech Inc. (TSX-V: QPT) (“Quest” or the “Company”), a Canadian based pharmaceutical company developing products to improve the quality o...